Organization
Duke University Medical Center
82 abstracts
2 posters
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.Org: O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Clinical Trial Development Division, Roswell Park Comprehensive Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center,
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,
Abstract
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).Org: New York University School of Medicine, The Ohio State University Comprehensive Cancer Center, Duke University Medical Center, Northwestern University, University of Colorado Comprehensive Cancer Center,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Abstract
Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS).Org: University of Chicago Pritzker School of Medicine, Fox Chase Cancer Center, University of Pennsylvania, Columbia University Mailman School of Public Health, New York, NY, Duke University Medical Center,
Abstract
Communicating cardiovascular health information and improving coordination with primary care: A Childhood Cancer Survivor Study randomized trial.Org: Fred Hutchinson Cancer Center, St. Jude Children's Research Hospital, University of Washington School of Medicine, Division of Haematology/Oncology, The Hospital for Sick Children, The Hospital for Sick Children,
Abstract
Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer.Org: Massachusetts General Hospital, Division of Hematology and Oncology/Department of Medicine, Boston, MA, Harvard Medical School, University of Pennsylvania,
Abstract
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.Org: Memorial Sloan Kettering Cancer Center, Duke University Medical Center, Vall d’Hebron University Hospital/VHIO, Institut Català d'Oncologia L´Hospitalet, Ramón y Cajal University Hospital,
Abstract
Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer.Org: Labcorp Oncology, OmniSeq Inc. (Labcorp), Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute,
Abstract
Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.Org: Labcorp Oncology, Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Patient-reported provider communication skills and adherence to recommended treatment in breast cancer.Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Duke University Medical Center, School of Social Work, The University of North Carolina at Chapel Hill, Breastcancer.org, Schools of Medicine and Public Health, University of California, Los Angeles,
Abstract
The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer.Org: Dana-Farber Cancer Institute, Duke Cancer Institute, Duke University Medical Center, The University of North Carolina at Chapel Hill, UT Southwestern Medical Center,
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,
Abstract
Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, MCC Physicians, Duke University Medical Center, Duke Cancer Institute,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
Sociodemographic differences in suicide/intentional self-harm among cancer survivors versus the general United States population.Org: University of Iowa College of Public Health, Henry Ford Health System, Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Duke University Medical Center,
Abstract
Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis.Org: OHSU Knight Cancer Institute, Duke Cancer Institute, Duke University Medical Center, James P. Wilmot Cancer Center, University of Rochester Medical Center,
Abstract
A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Illumina Inc., Fortrea Inc.,
Abstract
Quality of telehealth-provided cancer care in VA.Org: Duke University Medical Center, Durham, NC, Durham VA Medical Center, Michigan State University College of Human Medicine, East Lansing, MI,
Abstract
ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.Org: Massachusetts General Hospital, Brown University School of Medicine-Rhode Island Hospital, University of Washington School of Medicine, Wake Forest University Department of General Internal Medicine, Icahn School of Medcn At Mount Sinai,
Abstract
Unraveling the immunologic vulnerabilities of diffuse hemispheric glioma, H3 G34-mutant.Org: University of Minnesota, Caris Life Sciences, Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center, Miami Cancer Institute,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.Org: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, Duke University Trent Center for Bioethics Humanities and History of Medicine, Durham, NC, Icahn School of Medicine at Mount Sinai, New York, NY, Columbia University Mailman School of Public Health, New York, NY, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston, MA,
Abstract
Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.Org: Children's Hospital Colorado, Aurora, CO, Children's Oncology Group Statistics and Data Center, University of Florida, Baylor College of Medicine, Children's Hospital of Philadelphia, Roswell Park Cancer Institute Department of Cancer Prevention and Population Sciences,
Abstract
Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients.Org: Guardant Health Inc., Duke University Medical Center, Perlmutter Cancer Center, NYU Langone Health, NYU Langone Health, New York, NY, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX,
Abstract
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.Org: Sarah Cannon Research Institute/Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke University Medical Center, Huntsman Cancer Institute, University of Utah,
Abstract
Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.Org: Duke University Medical Center, Durham, NC, Personalis, Inc., Menlo Park, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Michigan, Rogel Comprehensive Cancer Center,
Abstract
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).Org: Mayo Clinic, Duke University Medical Center, University of Chicago, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Dana-Farber Cancer Institute,
Abstract
Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, ASCO, Alexandria, VA,
Abstract
Timing of allogeneic hematopoietic cell transplantation for myelofibrosis and other myeloproliferative neoplasms.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke Cancer Institute, Duke University Trent Center for Bioethics Humanities and History of Medicine, Durham, NC, Duke University Medical Center,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC,
Abstract
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.Org: Mayo Clinic, University Hospitals Gasthuisberg Leuven, KU Leuven, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Abstract
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).Org: Xilis, Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Xilis, Inc., Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, OmniSeq (Labcorp), Duke University Medical Center, Duke Cancer Institute, OmniSeq, Inc.,
Abstract
Distinct molecular features and potential therapeutic strategies for spinal cord gliomas.Org: Caris Life Sciences, Irving, TX, Penn State Milton S. Hershey Medical Center, Hershey, PA, Levine Cancer Institute, West Virginia University Camden Clark Medical Center, Duke University Medical Center,
Abstract
Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.Org: Xilis, Durham Veteran Affairs Medical Center, NC Medical Research, Xilis Inc, Xilis, Inc.,
Abstract
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).Org: Mass General Cancer Center, Mayo Clinic, University of California Irvine, Duke University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.Org: University of Texas MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Duke University Medical Center, City of Hope National Medical Center, Cliniques Universitaires Saint-Luc,
Abstract
A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).Org: Moffitt Cancer Center, Duke University Medical Center, Memgen,
Abstract
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).Org: Center for Innovations in Quality Effectiveness and Safety, Houston, TX, VA Boston Healthcare System, Boston, MA, Baylor College of Medicine,
Abstract
Healthcare access dimensions and uterine cancer survival: A National Cancer Database study.Org: Duke Medical Center, Duke University School of Medicine - Department of Population Health Sciences, Duke Cancer Institute, Division of Gynecologic Oncology, University of Pennsylvania, Duke University Medical Center,
Abstract
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.Org: Dana-Farber Cancer Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Georgetown University Hospital, Washington, DC, Lombardi Comprehensive Cancer Center, START San Antonio,
Abstract
MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,
Abstract
Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, Hospital Universitari Vall d'Hebron Research Institute, Roswell Park Cancer Institute,
Abstract
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
ctDNA detection in patients with brain metastases arising from solid tumors.Org: Duke University Medical Center, Department of Biostatistics & Bioinformatics & CALGB Statistical Center, Duke Cancer Institute, Duke University Cancer Institute, Dana-Farber Cancer Institute,
Abstract
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.Org: Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University, Thomas Jefferson University, START Midwest, Grand Rapids, MI, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, START San Antonio,
Abstract
Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?Org: BC Cancer Agency Vancouver Island Centre, Guardant Health Inc., Duke University Medical Center, Guardant Health, Inc., The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, American Society of Clinical Oncology, Herbert-Herman Cancer Center, Michigan Cancer Research Consortium,
Abstract
Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B), ± atezolizumab (A).Org: Duke University Medical Center, Mayo Clinic, Alliance Statistics and Data Management Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Duke University Medical Center, NRG Oncology, University of Iowa Hospitals and Clinics,
Abstract
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.Org: National Cancer Institute/National Institutes of Health, Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, Lehigh Valley Health Network,
Abstract
Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.Org: Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UT Southwestern Medical Center, Hôpital Pitié-Salpêtrière, NYU Department of Urology, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Swedish Cancer Institute, American Society of Clinical Oncology, Sutter Sacramento Medical Center, Cancer Treatment Centers of America – Chicago, part of City of Hope, Michigan Cancer Research Consortium,
Abstract
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Herbert-Herman Cancer Center, Michigan Cancer Research Consortium, American Society of Clinical Oncology, Cancer Treatment Centers of America – Chicago, part of City of Hope, Levine Cancer Institute,
Abstract
Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Durham, NC,
Abstract
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).Org: Duke Cancer Institute, Duke University Medical Center, Barbara Ann Karmanos Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, AdventHealth Cancer Institute, Orlando, FL,
Abstract
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Financial toxicity and quality of life in patients undergoing bone marrow transplant evaluation: A single center analysis.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Duke Cancer Institute Biostatistics, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, Levine Cancer Inst/Carolinas Medcl Ctr,
Abstract
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.Org: Duke Cancer Institute, Duke University Medical Center, Sarcoma Oncology Center, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Royal Marsden Hospital and Institute of Cancer Research,
Abstract
Breast cancer staging for patients with “low risk” disease: Are they all the same?Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Duke University Medical Center, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute,
Abstract
From the lab to the clinic: Lessons learned from a translational working group.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Durham, NC, COMET Study Patient Leadership Team, San Francisco, CA,
Abstract
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, Dornsife College of Letters, University of Southern California, Los Angeles, CA, University of California Los Angeles,
Abstract
TIGIT expression and outcomes in pembrolizumab treated patients with NSCLC.Org: OmniSeq Inc. (Labcorp), Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer.Org: UMass Chan Medical School, Duke University Medical Center,
Abstract
Comprehensive myeloid-derived suppressor cell (MDSC) immunophenotyping and functional assessment in chimeric antigen receptor (CAR) T therapy.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Duke University Cancer Institute,
Abstract
Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.Org: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Karmanos Cancer Institute, Wayne State University School of Medicine,
Abstract
Knowledge gaps and educational needs for common cancer therapy-related cardiovascular toxicities and related drug interactions.Org: UNC Eshelman School of Pharmacy, Duke University Medical Center, Baptist Health Systems, North Memorial Hill Health, Baghdad Heart Center,
Abstract
Racioethnic differences in missing data in the National Cancer Database: A window into inequities in cancer care.Org: Duke University Medical Center, Yale University, University of Pennsylvania Health System,
Abstract
Barriers and facilitators to implementing the Veterans Health Administration National Teleoncology Service: A qualitative descriptive study.Org: Durham VA Medical Center, Duke University Medical Center, Durham, NC, VA National Oncology Program and Durham VA Medical Center, Durham VA Health Care System,
Abstract
Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, Research Triangle Park, NC,